Retatrutide: beyond the scale

📄 5 PubMed citations

The triple-hormone agonist is famous for ~24% weight loss — but the trial data also point to cardiometabolic and joint signals. Here's what's actually published vs. what's still pending.

🔬 Written because retatrutide is the single most-discussed compound in our trend monitoring this week (ADA-2026 readouts; viral threads claiming knee-OA pain cut 75.8% and big lipid drops). Rather than repeat unverified social-media figures, this page is built strictly on peer-reviewed trials and clearly separates published results from the registrational TRIUMPH program that is still running.

Body-weight reduction at 48 weeks (12 mg, Phase 2 obesity)

HbA1c reduction in type 2 diabetes (12 mg, Phase 2)

Receptors targeted: GIP, GLP-1 & glucagon

Mechanism of Action

How It Works

🧬

Triple-receptor agonism

Retatrutide (LY3437943) activates GIP, GLP-1 and glucagon receptors. The added glucagon arm raises energy expenditure and acts on the liver — the proposed reason its metabolic effects extend past appetite suppression alone.

❤️

Cardiometabolic shift

Large weight loss in the Phase 2 trials was accompanied by improvements across cardiometabolic risk markers. Reviews of obesity medications describe lipid, blood-pressure and glycemic benefits as a class — retatrutide included.

🩸

Glycemic control

In type 2 diabetes, retatrutide lowered HbA1c by up to 2.02% at 24 weeks (vs ~0% placebo and outperforming dulaglutide at higher doses), with weight loss up to ~17% at 36 weeks.

🦵

Joint & sleep program

The Phase 3 TRIUMPH program is specifically testing retatrutide in knee osteoarthritis and obstructive sleep apnea alongside obesity — these readouts are pending, not yet published.

Data

What the Data Shows

12 mg

48-wk body-weight change (Phase 2 obesity)

−24.2%

8 mg

48-wk body-weight change

−22.8%

4 mg

48-wk body-weight change

−17.1%

Placebo

48-wk body-weight change

−2.1%

Bottom Line

Key Takeaways

✅ What We Know

In the Phase 2 obesity trial, 12 mg cut body weight 24.2% at 48 weeks; 83% of that group lost ≥15% of body weight (NEJM 2023, PMID 37366315).
In type 2 diabetes, retatrutide lowered HbA1c up to 2.02% at 24 weeks and reduced weight ~17% at 36 weeks (Lancet 2023, PMID 37385280).
A Phase 3 trial (TRANSCEND-T2D-1) confirmed glycemic and weight efficacy in T2D inadequately controlled on diet/exercise (Lancet 2026, PMID 42250575).
Reviews of obesity medications describe multisystem cardiometabolic benefits — lipids, blood pressure, glycemia — that accompany the weight loss (Lancet Diabetes Endocrinol 2026, PMID 42208956).
Knee osteoarthritis and obstructive sleep apnea are being formally tested in the registrational TRIUMPH program (Diabetes Obes Metab 2026, PMID 41090431).
A dose-dependent rise in heart rate peaked at 24 weeks and then declined (NEJM 2023, PMID 37366315).

⚠️ What We Don't Know

Retatrutide is investigational — not FDA-approved for any use as of mid-2026.
The viral 'knee OA pain reduced 75.8%' figure is NOT from a peer-reviewed publication; TRIUMPH OA/OSA results are still pending.
Exact lipid and blood-pressure percentage changes come from secondary/exploratory endpoints — treat specific social-media numbers with caution until full publications report them.
There is no completed long-term cardiovascular-outcomes trial for retatrutide yet.
Whether cardiometabolic gains are independent of weight loss has not been established in these trials.
Gastrointestinal side effects (nausea, diarrhea, vomiting) are common and dose-related.

FAQ

Frequently Asked Questions

Does retatrutide lower cholesterol and blood pressure?

In the Phase 2 trials, retatrutide's large weight loss was accompanied by improvements in cardiometabolic markers, and reviews of obesity medications describe lipid and blood-pressure benefits as part of this drug class. Exact percentage changes for retatrutide come from secondary endpoints and should be read from the full publications rather than social-media summaries.

How much weight do you lose on retatrutide?

In the Phase 2 obesity trial, the 12 mg dose reduced body weight by an average of 24.2% at 48 weeks, and 83% of participants on that dose lost at least 15% of their body weight (NEJM 2023).

Is retatrutide good for knee osteoarthritis?

Knee osteoarthritis is one of the conditions being formally tested in retatrutide's Phase 3 TRIUMPH program, but those results have not yet been published. Claims of a specific pain-reduction percentage circulating online are not from peer-reviewed data yet.

Does retatrutide help type 2 diabetes?

Yes — in a Phase 2 trial it lowered HbA1c by up to 2.02% at 24 weeks while also reducing weight, and a Phase 3 trial (TRANSCEND-T2D-1) has since confirmed glycemic and weight efficacy in people with type 2 diabetes.

Is retatrutide FDA approved?

No. As of mid-2026 retatrutide remains investigational and is in Phase 3 trials; it is not approved by the FDA for weight loss, diabetes, or any other indication.